Related Experiment Video
Updated: May 10, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Sunitinib as an anti-endometriotic agent
Manal A Abbas1, Ahmad M Disi, Mutasem O Taha
1Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan. manabbas@yahoo.com
Abstract:
Endometriosis is one of the most frequent diseases in gynecology. Currently available medical therapies for this disease are unsatisfactory. Based on current understanding of the pathogenic mechanisms in endometriosis especially the similarity between this disease and cancer, this study was designed to investigate the efficacy of the anticancer drug sunitinib in treating endometriosis. The effect of sunitinib on regression of endometriotic implants was studied in a rat surgical model. Sunitinib reduced cyst cross sectional area by 78.8% and caused complete cyst disappearance in 50% of the animals. Histologically, extensive fibrosis was detected in sunitinib-treated group with positive reaction in TUNEL assay indicating that apoptosis is a mechanism of action.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity
Drugs that Stabilize Microtubules
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs that Destabilize Microtubules
